Status:
UNKNOWN
Clinical Prognosis and Progression of Myasthenia Gravis Patients
Lead Sponsor:
Da, Yuwei, M.D.
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
15+ years
Brief Summary
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generali...
Detailed Description
This is a multicenter, observational cohort trial in the real-world clinical setting recruiting MG patients from Neurology Departments of 6 hospitals in different regions of China. Clinical manifestat...
Eligibility Criteria
Inclusion
- Age \>14.
- Clinical Diagnosis of MG with supporting evidence:
- unequivocal clinical response to pyridostigmine
- positive antibody testing
- decrement \>10% in repetitive nerve stimulations study (RNS) .
- Willingness to sample collection, imaging study and other disease-related examinations and assessments.
- Patients with informed consent.
Exclusion
- History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue.
- Age ≤14 years.
- Severe anxiety, depression or schizophrenia.
- Cognitive impairment or mini-mental state examination (MMSE) score ≤24.
- Severe systemic illness with life-expectancy less than 4 years.
- Unwillingness to consent for collection of biological samples.
- Inability to provide informed consent.
Key Trial Info
Start Date :
February 8 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04101578
Start Date
February 8 2017
End Date
December 31 2024
Last Update
August 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuan Wu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053